Copyright
©The Author(s) 2024.
World J Hepatol. Jul 27, 2024; 16(7): 1009-1017
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1009
Characteristics | n (%) or range |
Mean age (years) | 55 (28-80) |
Age > 50 year-old | 35 (66) |
Male:Female | 24:29 (45.3:54.7) |
Ethnicity | |
Asian | 51 (96.2) |
Hispanic | 1 (1.9) |
Other | 1 (1.9) |
BMI ≥ 25 kg/m2 | 17 (32.1) |
Clinical cirrhosis | 8 (15.1) |
Spleen size > 12 cm | 4 (7.7) |
HBV genotype | |
A | 2/24 (8.3) |
B | 15/24 (62.5) |
C | 6/24 (25) |
D | 1/24 (4.2) |
HBeAg + | |
Yes No | 15 (28.3) 38 (71.7) |
Mean ALT (U/L) | 24.8 (7-108) |
Mean AST (U/L) | 25.7 (15-89) |
Mean creatinine (mg/dL) | 0.86 (0.5–1.7) |
Mean APRI score | 0.37 (0.13-0.92) |
Mean FIB-4 score | 1.66 (0.49-5.33) |
Mean SWE score (kPa) | 7.05 (4-20.9) |
Platelets ≤ 120 × 109/L | 6 (11.3) |
ALT < 30/19 | APRI < 0.5 | FIB-4 < 1.45 | |||||||
Yes | No | P value | Yes | No | P value | Yes | No | P value | |
Gender (male) | 20/24 (83.3) | 15/29 (51.7) | 0.016 | 23/24 (95.8) | 28/29 (96.6) | 0.891 | 16/24 (66.7) | 15/29 (51.7) | 0.272 |
Age > 50 years | 23/35 (65.7) | 12/18 (66.7) | 0.945 | 34/35 (97.1) | 17/18 (94.4) | 0.625 | 17/18 (94.4) | 14/35 (40) | 0.001 |
BMI > 25 kg/m2 | 11/17 (64.7) | 24/36 (66.7) | 0.888 | 35/36 (97.2) | 16/17 (94.1) | 0.58 | 16/17 (94.1) | 15/36 (41.7) | 0.001 |
Cirrhosis | 4/8 (50) | 31/45 (68.9) | 0.299 | 6/8 (75) | 45/45 (100) | 0.001 | 2/8 (25) | 29/45 (64.4) | 0.037 |
Pre-Rx spleen size > 12 cm | 2/4 (50) | 33/48 (68.8) | 0.442 | 2/4 (50) | 48/48 (100) | 0.001 | 1/4 (25) | 30/48 (62.5) | 0.142 |
Platelets < 120 × 109/L Rx wk 24 | 1/4 (25) | 33/46 (71.7) | 0.078 | 2/4 (50) | 46/46 (100) | 0.001 | 1/4 (25) | 29/46 (63) | 0.221 |
APRI < 0.5 at Rx wk 24 | 33/45 (73.3) | 1/5 (20) | 0.027 | 45/45 (100) | 3/5 (60) | 0.001 | 29/45 (64.4) | 1/5 (20) | 0.106 |
FIB-4 < 1.45 at Rx wk 24 | 22/31 (71) | 12/19 (63.1) | 0.399 | 31/31 (100) | 17/19 (89.5) | 0.156 | 27/31 (87.1) | 3/19 (15.8) | 0.001 |
ALT < 30/19 U/L at Rx wk 24 | 28/37 (75.7) | 7/16 (43.8) | 0.024 | 36/37 (97.2) | 15/16 (93.8) | 0.534 | 20/37 (54) | 11/16 (68.8) | 0.319 |
AST < 30/19 U/L at Rx wk 24 | 25/34 (73.5) | 10/19 (52.6) | 0.123 | 34/34 (100) | 17/19 (89.5) | 0.054 | 23/34 (67.6) | 8/19 (42.1) | 0.07 |
ALT < 35/25 at Rx wk 24 | 33/45 (73.3) | 2/8 (25) | 0.008 | 44/45 (97.8) | 7/8 (87.5) | 0.16 | 25/45 (55.6) | 6/8 (75) | 0.304 |
AST < 35/25 at Rx wk 24 | 34/49 (69.4) | 1/4 (25) | 0.071 | 48/49 (97.9) | 3/4 (75) | 0.021 | 28/49 (57.1) | 3/4 (75) | 0.486 |
- Citation: Huynh T, Bui DM, Zhou TX, Hu KQ. Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. World J Hepatol 2024; 16(7): 1009-1017
- URL: https://www.wjgnet.com/1948-5182/full/v16/i7/1009.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i7.1009